Annual Statement of Changes in Beneficial Ownership (5)
24 Settembre 2014 - 1:33AM
Edgar (US Regulatory)
FORM 5
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
[
X
]
Form 3 Holdings Reported
[ ]
Form 4 Transactions Reported
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0362
Estimated average burden
hours per response...
1.0
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BRISTOL MYERS SQUIBB CO
|
2. Issuer Name
and
Ticker or Trading Symbol
KYTO BIOPHARMA INC [KBPH]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
345 PARK AVENUE,
|
3. Statement for Issuer's Fiscal Year Ended
(MM/DD/YYYY)
3/31/2010
|
(Street)
NEW YORK, NY 10154
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form Filed by One Reporting Person
_
X
_ Form Filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
|
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
|
|
3
(1)
|
|
|
|
1300000
(1)
|
I
(1)
|
By Medarex, L.L.C.
(1)
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
|
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
Bristol-Myers Squibb Company ("BMS") recently identified its indirect ownership of 1,300,000 shares of common stock of Kyto Biopharma, Inc. ("Kyto"). These shares are owned directly by Medarex, L.L.C. (formerly known as Medarex, Inc.) ("Medarex"), a wholly-owned subsidiary of BMS. BMS acquired Medarex on September 1, 2009. At that time, Medarex owned 1,300,000 Kyto shares but only provided BMS with a stock certificate, in the name of Kyto's predecessor company B. Twelve, Inc., for 400,000 shares.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
BRISTOL MYERS SQUIBB CO
345 PARK AVENUE
NEW YORK, NY 10154
|
|
X
|
|
|
MEDAREX INC
C/O BRISTOL-MYERS SQUIBB COMPANY
345 PARK AVENUE
NEW YORK, NY 10154
|
|
X
|
|
|
Signatures
|
Bristol-Myers Squibb Company, By: /s/ Katherine R. Kelly, Vice President & Assistant Secretary
|
|
9/23/2014
|
**
Signature of Reporting Person
|
Date
|
Medarex, L.L.C. (formerly known as Medarex, Inc.), By: /s/ Katherine R. Kelly, Secretary
|
|
9/23/2014
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Grafico Azioni Kyto Technology and Life... (CE) (USOTC:KBPH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kyto Technology and Life... (CE) (USOTC:KBPH)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Kyto Technology and Life Science Inc (CE) (OTCMarkets): 0 articoli recenti
Più Kyto Biopharma Inc Articoli Notizie